Is the Hype Real? Targeted and Immunotherapy in Resectable Non-Small Cell Lung Cancer

Moderator(s)

• 

  Robert Merritt, MD

  Director of Thoracic Surgery
  Thoracic Surgery Division, Department of Surgery, The Ohio State University Wexner Medical Center
  Columbus, Ohio, United States

  Disclosure(s): Astra Zeneca: Advisory Board (Ongoing); Intuitive Surgical: Speaker (Ongoing)
• 

  Jason Long, MD, MPH (he/him/his)

  Director, UNC Lung Cancer Screening Clinic; Director, UNC Robotic Thoracic Surgery; Associate Professor of Surgery
  University of North Carolina Department of Surgery
  Chapel Hill, North Carolina, United States

  Disclosure(s): DaVinci Intuitive Surgical: Consultant (Ongoing); Medscape: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Stryker: Consultant (Ongoing)

Presentations:

• 9:45 AM – 9:55 AM PT

  Pathologic Downstaging Following Neoadjuvant Chemoimmunotherapy for Locally Advanced Lung Cancer is Associated with Survival Comparable to Early Stage-Matched Disease
  

  Charles D. Logan, MD – Surgical Outcomes and Quality Improvement Center, Department of Surgery, Northwestern University, Feinberg School of Medicine
• 9:55 AM – 10:05 AM PT

  Nomogram to Predict Adjuvant Chemotherapy Benefit in Stage 1B/2A Lung Cancer
  

  Kayla Rizzo, DO – William Beaumont Army Medical Center
• 10:05 AM – 10:15 AM PT

  Afatinib as Neoadjuvant Treatment of Stage III EGFR-Mutant Non-Small Cell Lung Cancer (TEAM-LungMate 004): A Prospective, Single-Arm, Phase II Study
  

  Dongliang Bian – Shanghai Pulmonary Hospital
• 10:15 AM – 10:25 AM PT

  Summary of key trials on perioperative immunotherapy and Targeted Molecular Therapy in NSCLC
  

  David R. Jones, MD – Memorial Sloan Kettering Cancer Center
• 10:25 AM – 10:45 AM PT

  Expert Panel/Q&A
  

  David R. Jones, MD – Memorial Sloan Kettering Cancer Center

  Jessica S. Donington, MD (she/her/hers) – University of Chicago

  Nathaniel R. Evans, III, MD (he/him/his) – Thomas Jefferson University